Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL investigators.

Lancet. 2008 Sep 6;372(9641):817-21. doi: 10.1016/S0140-6736(08)61171-X. Epub 2008 Aug 29.

PMID:
18757091
2.

Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.

Bruguera Cortada J, Varela A.

Am J Cardiovasc Drugs. 2009;9 Suppl 1:9-12. doi: 10.2165/1153162-S0-000000000-00000. Review.

PMID:
20000882
3.

[Heart rate: a risk factor or an epiphenomenon?].

Metra M, Zacà V, Lombardi C, Bugatti S, Dei Cas L.

G Ital Cardiol (Rome). 2010 Mar;11(3):209-20. Review. Italian.

PMID:
20550061
4.

Heart rate as a treatable cardiovascular risk factor.

Tardif JC.

Br Med Bull. 2009;90:71-84. doi: 10.1093/bmb/ldp016. Epub 2009 May 27. Review.

PMID:
19474056
5.

Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.

Perry CM.

Am J Cardiovasc Drugs. 2012 Dec 1;12(6):415-26. doi: 10.2165/11209990-000000000-00000. Review.

PMID:
23181944
6.

Heart rate in coronary syndromes and heart failure.

Orso F, Baldasseroni S, Maggioni AP.

Prog Cardiovasc Dis. 2009 Jul-Aug;52(1):38-45. doi: 10.1016/j.pcad.2009.05.006. Review.

PMID:
19615492
7.

[The resting heart rate].

Bemelmans RH, Visseren FL.

Ned Tijdschr Geneeskd. 2014;158:A6931. Review. Dutch.

PMID:
24666528
8.
9.

Ivabradine: recent and potential applications in clinical practice.

Riccioni G.

Expert Opin Pharmacother. 2011 Feb;12(3):443-50. doi: 10.1517/14656566.2011.548321. Review.

PMID:
21254949
10.

An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.

Rosa GM, Ferrero S, Ghione P, Valbusa A, Brunelli C.

Expert Opin Drug Metab Toxicol. 2014 Feb;10(2):279-91. doi: 10.1517/17425255.2014.876005. Epub 2013 Dec 31. Review.

PMID:
24377458
11.

Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.

Canet E, Lerebours G, Vilaine JP.

Ann N Y Acad Sci. 2011 Mar;1222:90-9. doi: 10.1111/j.1749-6632.2011.05960.x. Review.

PMID:
21434947
12.

Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.

Ferrari R, Ceconi C.

Expert Rev Cardiovasc Ther. 2011 Aug;9(8):959-73. doi: 10.1586/erc.11.99. Review.

PMID:
21878041
13.

Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.

Cammarano C, Silva M, Comee M, Donovan JL, Malloy MJ.

Clin Ther. 2016 Feb;38(2):387-95. doi: 10.1016/j.clinthera.2015.12.018. Epub 2016 Feb 1. Review.

PMID:
26839043
14.

Resting heart rate in cardiovascular disease.

Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group.

J Am Coll Cardiol. 2007 Aug 28;50(9):823-30. Epub 2007 Aug 13. Review.

15.

[Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study?].

Perna GP, Battistoni I, Angelini L.

G Ital Cardiol (Rome). 2015 Mar;16(3):155-60. doi: 10.1714/1820.19824. Review. Italian.

PMID:
25837459
16.

Ivabradine: beyond heart rate control.

Riccioni G, Vitulano N, D'Orazio N.

Adv Ther. 2009 Jan;26(1):12-24. doi: 10.1007/s12325-008-0130-y. Epub 2009 Jan 22. Review.

PMID:
19165437
17.

Resting heart rate and outcomes in patients with cardiovascular disease: where do we currently stand?

Menown IB, Davies S, Gupta S, Kalra PR, Lang CC, Morley C, Padmanabhan S.

Cardiovasc Ther. 2013 Aug;31(4):215-23. doi: 10.1111/j.1755-5922.2012.00321.x. Review.

18.

Heart rate and heart failure. Not a simple relationship.

Heusch G.

Circ J. 2011;75(2):229-36. Epub 2010 Oct 28. Review.

19.

Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.

Borer JS, Deedwania PC, Kim JB, Böhm M.

Am J Cardiol. 2016 Dec 15;118(12):1948-1953. doi: 10.1016/j.amjcard.2016.08.089. Epub 2016 Sep 15. Review.

PMID:
27780557
20.

Rate control with ivabradine: angina pectoris and beyond.

Parakh N, Bhargava B.

Am J Cardiovasc Drugs. 2011;11(1):1-12. doi: 10.2165/11584840-000000000-00000. Review.

PMID:
21090826

Supplemental Content

Support Center